• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 30, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Oncotarget: Australian experience of peptide receptor radionuclide therapy

Bioengineer by Bioengineer
July 7, 2020
in Health
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Oncotarget Volume 11, Issue 27 published “Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours” by Lim et al. which reported peptide receptor radionuclide therapy (PRRT) is an approved treatment modality for gastro

IMAGE

Credit: Correspondence to – Lisi Elizabeth Lim – [email protected]

Oncotarget Volume 11, Issue 27 published “Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours” by Lim et al. which reported peptide receptor radionuclide therapy (PRRT) is an approved treatment modality for gastroenteropancreatic neuroendocrine tumours, although Phase III randomised clinical trial data is not available for NETs of other site of origin, in practice, PRRT is used more widely in clinical practice, based on its mechanism of targeting the somatostatin receptor.

A retrospective chart review of patients with TC and AC who received 177Lu-dotatate PRRT between January 2002 and June 2019 in six hospitals across Australia was undertaken.

  1. Forty-eight patients received a median of four 177Lu-dotatate treatments.
  2. The response rate to 177Lu-dotatate was 33%, with a median overall survival of 49 months, at a median follow up of 33 months.
  3. 177Lu-dotatate PRRT in patients with lung NETs is used in real world practice, where it appears well-tolerated with some efficacy.

Dr. Lisi Elizabeth Lim from The Department of Medical Oncology at Monash Health said “Neuroendocrine tumours (NETs) are uncommon malignancies, comprising 0.5% of all cancers.“

Lung is the primary site for approximately 20?25% of NETs; conversely NETs comprises about 2% of all lung malignancies.

New trials have demonstrated that adequate numbers of patients can be recruited through global collaborations, both for protocols specific to lung NETs and those recruiting patients with NETs from a variety of sites.

PRRT is a firmly established treatment modality for advanced GEP NETs following the publication of the landmark NETTER-1 trial, where patients with progressive midgut NET were randomised to receive 177Lu-dotatate with ongoing octreotide long-acting repeatable therapy, or high dose octreotide LAR alone.

The significant benefit for PRRT in midgut NETs has provoked debate about whether randomised trials are required to prove its efficacy in NETs of other site of origin.

“The significant benefit for PRRT in midgut NETs has provoked debate about whether randomised trials are required to prove its efficacy in NETs of other site of origin.”

NET consensus guidelines either omit specific comment on the use of PRRT in lung NETs, or state that imaging with SSTR-PET can assist in identifying patients who may benefit from PRRT. The Lim Research Team concluded in their Oncotarget Research Paper that further data will be forthcoming also from studies of PRRT in patients with SSTR-expressing tumours of histologies other than NET. The randomised phase II LUTHREE trial is inclusive of all SSTR positive tumour types, and is not restricted to NETs. The POLNETS trial is also extending the use of PRRT to paraganglioma and pheochromocytoma, in addition to advanced NETs of any site of origin.

Sign up for free Altmetric alerts about this article

DOI – https://doi.org/10.18632/oncotarget.27659

Full text – https://www.oncotarget.com/article/27659/text/

Correspondence to – Lisi Elizabeth Lim – [email protected].

Keywords –
lung,
carcinoid,
atypical,
neuroendocrine,
peptide receptor radionuclide therapy

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud – https://soundcloud.com/oncotarget
Facebook – https://www.facebook.com/Oncotarget/
Twitter – https://twitter.com/oncotarget
LinkedIn – https://www.linkedin.com/company/oncotarget
Pinterest – https://www.pinterest.com/oncotarget/
Reddit – https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
Ryan James Jessup
[email protected]

Original Source

https://www.oncotarget.com/news/pr/australian-experience-of-peptide-receptor-radionuclide-therapy/

Related Journal Article

http://dx.doi.org/10.18632/oncotarget.27659

Tags: cancerCarcinogensMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

How Involvement in Research Benefits Health Care Staff

August 30, 2025

Pemafibrate’s Long-Term Safety in Hyperlipidemia Treatment

August 30, 2025

Innovative Methotrexate Treatment for Non-Tubal Ectopic Pregnancy

August 30, 2025

Canine Therapy: Alleviating Student Stress and Anxiety

August 30, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    152 shares
    Share 61 Tweet 38
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    82 shares
    Share 33 Tweet 21

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

How Involvement in Research Benefits Health Care Staff

Pemafibrate’s Long-Term Safety in Hyperlipidemia Treatment

Innovative Methotrexate Treatment for Non-Tubal Ectopic Pregnancy

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.